Allergan reports Q2 net revenue increase

Allergan reported its second quarter 2017 operations performance, including total net revenues of $4 billion, which was a 9% increase from the same quarter a year earlier.

The revenue growth was driven by Botox (onabotulinumtoxinA) and the Juvéderm (injectible gel) collection, and the addition of Alloderm (tissue matrix) and CoolSculpting (cryolipolysis), according to a news release from Allergan.

Decreased revenues from products including Restasis (cyclosporine), which was affected by the quarter’s trade buying patterns, partially offset the increase. Restasis net revenues decreased 9.4% compared with the prior year quarter, according to the release.

"With our strong first half performance and solid outlook for the remainder of the year, we are raising our full-year guidance," Brent Saunders, chairman and CEO of Allergan, stated in the release. “Revenue growth in the second quarter was powered by significant year-over-year gains from many of our top products, solid contribution from our launch products and successful integrations of LifeCell and Zeltiq.”

Allergan’s facial aesthetics franchise saw a 9.1% increase in revenues compared with the same period the prior year.

Allergan’s medical dermatology franchise products, including Aczone (dapsone) had decreases in net revenues, according to the release.

GAAP operating loss from continuing operations in the second quarter of $902.4 million, Allergan reported.

Reference: www.allergan.com